Rational Design, Synthesis, and Structure-Activity Relationship of a Novel Isoquinolinone-Based Series of HBV Capsid Assembly Modulators Leading to the Identification of Clinical Candidate AB-836JOURNAL OF MEDICINAL CHEMISTRYIF6.82024-09-042PRE
Conformationally Constrained Isoquinolinones as Orally Efficacious Hepatitis B Capsid Assembly ModulatorsACS MEDICINAL CHEMISTRY LETTERSIF42024-09-031PRE
Discovery of C-Linked Nucleoside Analogues with Antiviral Activity against SARS-CoV-2发现对SARS-CoV-2具有抗病毒活性的C-连接核苷类似物ACS INFECTIOUS DISEASESIF3.82024-04-233PRE
Nomenclature of HBV core protein-targeting antiviralsNature Reviews Gastroenterology & HepatologyIF512022-10-070PRE
Safety, pharmacokinetics, and antiviral activity of the capsid inhibitor AB-506 from Phase 1 studies in healthy subjects and those with hepatitis BHEPATOLOGY COMMUNICATIONSIF4.62022-10-0415OAAI
The identification of highly efficacious functionalised tetrahydrocyclopenta[c]pyrroles as inhibitors of HBV viral replication through modulation of HBV capsid assemblyRSC MEDICINAL CHEMISTRYIF3.62022-01-018OA
Preclinical Profile of AB-423, an Inhibitor of Hepatitis B Virus Pregenomic RNA EncapsidationANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52018-06-0164OAAI
Preclinical antiviral drug combination studies utilizing novel orally bioavailable investigational agents for chronic hepatitis B infection: AB-506, a next generation HBV capsid inhibitor, and AB-452, a HBV RNA destabilizerJOURNAL OF HEPATOLOGYIF332018-04-017PREAI
Discovery of Novel Allosteric HCV NS5B Inhibitors. 2. Lactam-Containing Thiophene CarboxylatesACS MEDICINAL CHEMISTRY LETTERSIF42017-01-3110OAAI
Discovery of Novel Thiophene-Based, Thumb Pocket 2 Allosteric Inhibitors of the Hepatitis C NS5B Polymerase with Improved Potency and Physicochemical ProfilesJOURNAL OF MEDICINAL CHEMISTRYIF6.82016-07-0114PREAI
IN VITRO AND IN VIVO ANTIVIRAL ACTIVITIES OF AB-423 A POTENT SMALL MOLECULE INHIBITOR OF HEPATITIS B VIRUS CAPSID ASSEMBLYJOURNAL OF HEPATOLOGYIF332016-01-011PREAI
Nonstructural Protein 5A (NS5A) and Human Replication Protein A Increase the Processivity of Hepatitis C Virus NS5B Polymerase Activity In VitroJOURNAL OF VIROLOGYIF3.82015-01-019OAAI
In Vitro Phenotypic Characterization of Hepatitis C Virus NS3 Protease Variants Observed in Clinical Studies of TelaprevirANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52013-12-0125OA
Discovery of Thienoimidazole-Based HCV NS5A Genotype 1a and 1b InhibitorsACS MEDICINAL CHEMISTRY LETTERSIF42013-02-0814OA
Characterization of V36C, a Novel Amino Acid Substitution Conferring Hepatitis C Virus (HCV) Resistance to Telaprevir, a Potent Peptidomimetic Inhibitor of HCV ProteaseANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52010-06-0113OAAI
In Vitro and In Vivo Isotope Effects with Hepatitis C Protease Inhibitors: Enhanced Plasma Exposure of Deuterated Telaprevir versus Telaprevir in RatsJOURNAL OF MEDICINAL CHEMISTRYIF6.82009-11-06150PREAI
Novel dual-targeting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: Intelligent design and evolution through the judicious use of structure-guided design and stucture-activity relationshipsJOURNAL OF MEDICINAL CHEMISTRYIF6.82008-08-09244PREAI
Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compoundsANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52007-02-0192OAAI
In vitro characterization of the antibacterial spectrum of novel bacterial type II topoisomerase inhibitors of the aminobenzimidazole classANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52006-04-0181OA
Inhibition of antibiotic efflux in bacteria by the novel multidrug resistance inhibitors biricodar (VX-710) and timcodar (VX-853)ANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52004-11-0197OAAI